3,200 Shares in GSK plc (NYSE:GSK) Purchased by Barometer Capital Management Inc.

Barometer Capital Management Inc. acquired a new position in shares of GSK plc (NYSE:GSKFree Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,200 shares of the pharmaceutical company’s stock, valued at approximately $119,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Versant Capital Management Inc boosted its holdings in shares of GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 676 shares during the period. BKM Wealth Management LLC purchased a new position in shares of GSK during the 4th quarter valued at $32,000. Jones Financial Companies Lllp grew its holdings in shares of GSK by 62.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock valued at $48,000 after acquiring an additional 509 shares in the last quarter. Princeton Global Asset Management LLC increased its stake in shares of GSK by 54.3% in the fourth quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after acquiring an additional 533 shares during the last quarter. Finally, Armstrong Advisory Group Inc. raised its holdings in shares of GSK by 189.1% during the fourth quarter. Armstrong Advisory Group Inc. now owns 1,619 shares of the pharmaceutical company’s stock worth $60,000 after acquiring an additional 1,059 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Up 0.8 %

Shares of GSK stock opened at $41.38 on Wednesday. The stock’s 50 day simple moving average is $42.57 and its 200 day simple moving average is $40.85. GSK plc has a twelve month low of $33.67 and a twelve month high of $45.92. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87. The company has a market capitalization of $85.76 billion, a price-to-earnings ratio of 14.87, a PEG ratio of 1.25 and a beta of 0.66.

GSK (NYSE:GSKGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. The business had revenue of $9.34 billion during the quarter, compared to analysts’ expectations of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. As a group, research analysts predict that GSK plc will post 4.11 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be issued a dividend of $0.3762 per share. This represents a $1.50 dividend on an annualized basis and a yield of 3.64%. This is a boost from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. GSK’s dividend payout ratio is 53.26%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on GSK. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Finally, The Goldman Sachs Group assumed coverage on shares of GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $47.00.

Get Our Latest Stock Report on GSK

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Recommended Stories

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.